Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene…
Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus…
Broken String Biosciences Unveils Catalyst Program to Accelerate Gene Editing Therapy Development Broken String Biosciences a leader in advancing gene editing safety, has officially launched its Catalyst Early Access Program…
Merck Begins Phase 3 Trial of Zilovertamab Vedotin for DLBCL Treatment DLBCL Treatment Merck known as MSD outside the United States and Canada, has officially announced the initiation of waveLINE-010,…
Know Labs Technology Licensing (KTL) Announces Official Client Partnership Know Labs is pleased to announce the official launch of its structured client engagement process for Know Labs Technology Licensing (KTL),…
GoodRx the leading prescription savings platform in the United States, has announced the appointment of Christopher A. McGinnis as its new Chief Financial Officer (CFO), effective February 4, 2025. McGinnis,…
Onc.AI Secures FDA Breakthrough Device Designation for AI-Powered CT Response Model Onc.AI, FDA a pioneering digital health company specializing in AI-driven oncology clinical management solutions, has achieved a significant milestone…
Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Announce Exit from Pharmaceutics International, Inc. A consortium of investors, including Pharmascience Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital,…
Dr. Hong Jiang: Advancing Immunology from Scientific Breakthroughs to Clinical Applications Dr. Hong Jiang, MD, PhD, has been recognized in Marquis Who’s Who for her outstanding contributions to immunology and…
Claxton Copeland III Recognized for Excellence in Clinical Research Claxton Copeland III has been selected for inclusion in Marquis Who’s Who, a prestigious recognition that highlights individuals based on their…
Marquis Cheryl Custard: A Pillar of Excellence in Research and Development Cheryl Custard has earned a prestigious spot in Marquis Who’s Who , a recognition reserved for individuals who demonstrate…
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a…